White House Backs Trump Cannabis Policy as 'Overwhelmingly Popular'

The White House doubled down on the Trump administration's cannabis approach, with Press Secretary statements emphasizing broad voter approval and patient access benefits. The defense comes as federal marijuana policy continues evolving across multiple agencies, creating ripple effects throughout the $30 billion legal cannabis market.

The administration's positioning reflects shifting political calculations around cannabis reform. With 38 states operating medical programs and 24 allowing adult-use sales, federal officials increasingly acknowledge marijuana's mainstream acceptance. This rhetoric marks a notable departure from traditional Republican messaging on cannabis issues.

Cannabis companies monitor federal signals closely, as policy shifts directly impact banking access, interstate commerce potential, and tax burdens. Multi-state operators like Curaleaf (CURA) and Green Thumb Industries (GTII) face effective tax rates exceeding 70% under Section 280E restrictions, making federal reform a critical catalyst for profitability improvements.

The patient-focused messaging aligns with broader rescheduling discussions at the Drug Enforcement Administration. Moving marijuana from Schedule I to Schedule III would maintain medical research pathways while potentially easing regulatory constraints on state-legal operators. Industry analysts view any federal accommodation as positive for sector valuations.

Political momentum around cannabis reform accelerates as election cycles approach. The administration's public support signals recognition that marijuana prohibition lacks voter backing, particularly among key demographics. This dynamic creates tailwinds for cannabis stocks while potentially accelerating legislative action on banking reform and federal coordination with state programs.